Prostate drug linked to better survival in esophageal and gastric cancer

Swedish researchers found that patients taking 5α-reductase inhibitors—commonly prescribed for prostate conditions—showed improved survival rates when diagnosed with esophageal or gastric cancer. The finding, based on nationwide health records, could reshape treatment strategies and open a new therapeutic avenue for two of the deadliest cancer types.

Originaltitel: Use of 5α-reductase inhibitors and survival of oesophageal and gastric cancer in a nationwide Swedish cohort study